Skip to main content
IMMUPHARMA PLC logo

IMMUPHARMA PLC — Investor Relations & Filings

Ticker · IMM ISIN · GB0033711010 LEI · 213800VZKGHXC7VUS895 IL Professional, scientific and technical activities
Open in API
Filings indexed 443 across all filing types
Latest filing 2022-10-07 Regulatory Filings
Country GB United Kingdom
Listing IL IMM

About IMMUPHARMA PLC

https://www.immupharma.co.uk/

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The company's primary focus is on creating novel treatments for serious medical conditions with significant unmet needs. Its core activities involve advancing a pipeline of drug candidates through research and various stages of clinical development, leveraging its expertise in peptide technology.

Recent filings

Filing Released Lang Actions
Company Secretary Change
Regulatory Filings Classification · 1% confidence The document starts with 'RNS Number' and is dated '07 October 2022'. It announces the 'Appointment of Company Secretary' for ImmuPharma PLC. The text explicitly mentions being provided by 'RNS, the news service of the London Stock Exchange' and that it contains inside information stipulated under UK Market Abuse Regulation. This structure and content strongly indicate a general regulatory announcement disseminated via the London Stock Exchange's Regulatory News Service (RNS). Since the specific event (appointment of a secretary) does not fit into the highly specific categories like Director's Dealing (DIRS), Management Change (MANG), or Capital Change (CAP), the most appropriate classification is the general regulatory filing category, RNS.
2022-10-07 English
Lupuzor Update
Legal Proceedings Report Classification · 1% confidence The document begins with 'RNS Number' and is dated '30 September 2022'. It contains an update regarding a drug (Lupuzor™) and regulatory feedback from the FDA. The text explicitly mentions that the information is being provided via RNS, which is the news service of the London Stock Exchange, and that it contains inside information stipulated under Market Abuse Regulation. Since this is a general, timely announcement of corporate/regulatory news that doesn't fit the specific categories like ER, IR, or DIRS, and is distributed via the RNS system, the most appropriate classification is Regulatory Filings (RNS). The document length (4740 chars) is not extremely short, but the nature of the distribution channel (RNS) and the content (a general update on regulatory progress) strongly suggest this category, which serves as a general regulatory announcement fallback.
2022-09-30 English
Interim Results or the 6mths Ended 30 June 2022
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM RESULTS' for the six months ended 30 June 2022. It contains detailed financial statements, including loss for the period, R&D expenses, administrative expenses, and cash balances, as well as a comprehensive management discussion and analysis of the company's pipeline and capital structure. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2022
2022-09-30 English
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document is very short (1933 characters) and contains the header 'RNS Number : 2282B' and mentions 'RNS, the news service of the London Stock Exchange'. The content describes a 'Second Price Monitoring Extension' for a security, which is a specific operational announcement related to trading halts or volatility controls on the exchange. This type of immediate, non-periodic regulatory update that doesn't fit into standard financial reporting categories (like 10-K, ER, or IR) is best classified as a general Regulatory Filing (RNS), as it is distributed via the RNS system.
2022-09-29 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1916 characters) and contains the header 'RNS Number : 2270B' and mentions 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content itself is a brief announcement regarding a 'Price Monitoring Extension' for a security's auction call period. This is a general regulatory announcement that does not fit into specific financial reporting categories like 10-K, ER, or IR. According to the definitions, this falls under the general regulatory announcement category, which is RNS.
2022-09-29 English
Written Response received from the FDA
Legal Proceedings Report Classification · 1% confidence The document is identified by the 'RNS Number' header and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' It announces a specific corporate event—receiving a written response from the FDA regarding a drug program—and concludes with contact information and standard RNS disclaimers. Since it is a general regulatory announcement disseminated via the RNS system that does not fit into more specific categories like Director's Dealing (DIRS), Earnings Release (ER), or Capital Change (SHA), it falls under the general Regulatory Filings category (RNS). The document length (3810 chars) is short, suggesting it is an announcement rather than the full underlying report.
2022-09-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.